AstraZeneca’s Farxiga Wins China Approval for Chronic Kidney Disease
UK pharma giant AstraZeneca (AZ, NASDAQ: AZN) announced a new approval for Farxiga (dapagliflozin), its...
Chronic disease
NMPA Suspends UCB’s Keppra Over Labeling Issues, Prompting Recall
The National Medical Products Administration (NMPA) has suspended approval for UCB’s Keppra (levetiracetam) concentrated solution...
Nuance Pharma Gets NMPA Green Light for Ensifentrine COPD Trials in China
China-based Nuance Pharma has secured approval from the National Medical Products Administration (NMPA) to conduct...
Lundbeck’s Vyepti Fails to Accelerate China Launch via SUNLIGHT Trial
Lundbeck’s attempt to fast-track migraine drug Vyepti (eptinezumab) into China and Asia via the SUNLIGHT...
Baheal Pharmaceutical Partners with Takeda to Boost Drug Commercialization in China
China-based health services and distribution giant Baheal Pharmaceutical Group has entered into a partnership with...
Ascletis Pharma’s Gannex Initiates DDI Study for ASC42 in PBC
Ascletis Pharma Inc. (HKG: 1672) announced that its wholly – owned US unit, Gannex, has...
Elite Pharma Raises RMB100m in Series B Financing for Drug Delivery Tech
Shanghai-based Elite Pharmaceutical Technology Inc. has reportedly raised nearly RMB100 million (USD14.8 million) in a...
Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center
US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...
Kintor Pharma Completes GT20029 Phase I Study for Hair Loss and Acne
China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced the completion of dosing all 92 subjects in...
Sciwind’s XW003 Shows Positive Weight Loss Results in Phase Ic/IIa Study
Hangzhou-based Sciwind announced positive interim topline results from a 26-week Phase Ic/IIa clinical study of...
Coherent Biopharma Raises Series B Funds to Advance Bi-XDC Pipeline
Coherent Biopharma Ltd, a Suzhou-based specialist in bispecific-ligand drug conjugates (Bi-XDC), has reportedly raised an...
Unicycive Therapeutics Licenses Renazorb to Lee’s Pharma for Asian Markets
U.S.-based biotech Unicycive Therapeutics, Inc. (NASDAQ: UNCY) announced a licensing agreement with Hong Kong-listed Lee’s...
Hainan Shuangcheng to Transfer Triptorelin Assets to Chongqing Lummy for USD 4.7M
Hainan Shuangcheng Pharmaceutical Co., Ltd (SHA: 002693) will transfer all tangible and intangible assets and...
Pica Partners with BrainCo to Launch ADHD Product in China
Shanghai-based primary healthcare digital platform Pica, developed by Wuxi AppTec in 2016, has partnered with...
Novaremed AG Licenses NRD.E1 to NeuroFront for Greater China Development
Switzerland-based Novaremed AG has entered into a licensing agreement with China’s NeuroFront (Shanghai) Co., Ltd,...
Henlius Biotech’s HLX14 Biosimilar Wins TGA Approval for Global Phase III Osteoporosis Study
China-based Shanghai Henlius Biotech Inc. (HKG: 2696) received approval from Australia’s Therapeutic Goods Administration (TGA)...
Luye Pharma’s Rotigotine Microspheres Meet Phase III Goals in Parkinson’s Study
China-based Luye Pharma Group (HKG: 2186) announced that its Phase III clinical study for rotigotine...
Roche’s Chugai Launches Edirol in China for Postmenopausal Osteoporosis
Swiss pharma giant Roche’s subsidiary Chugai Pharmaceutical Co Ltd has officially launched Edirol (eldecalcitol), an...
Grand Pharma Acquires Stake in Xeltis and Licenses aXess for Hemodialysis in Greater China
China-based Grand Pharmaceutical Group Limited (HKG: 0512) announced the acquisition of an 11% stake in...
Novartis’ Aimovig Launches in China via GBA Early Access Scheme for Migraine Treatment
Swiss pharma giant Novartis’ (NYSE: NVS) migraine therapy Aimovig (erenumab) was administered for the first...